Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

108 Solvay Global Annual Report 2005 The dividend is payable at the following institutions: – Fortis Bank S.A., Montagne du Parc 3 - 1000 Brussels – ING Belgium South West Europe, Cours Saint Michel 60 – B-1040 Brussels – KBC Bank N.V., Havenlaan 2 – B-1080 Brussels – Fortis Banque Luxembourg, 50, av. J.F. Kennedy, L-2951 Luxembourg – Crédit Suisse, Paradeplatz 8 – CH-8021 Zürich – Deutsche Bank, Taunusanlage 12 – D-60262 Frankfurt-am-Main – ABN Amro B.V., Foppingsdreef 22/AA 3330 – NL- 1102 BS Amsterdam. For ADRs the dividend is payable by Morgan ADR Service Center, P.O. Box 8205 – USA-Boston, MA 02266-8205. Shareholder and investor relations Active and much appreciated fi nancial communication Best Financial Information Prize In 2005, as in 2004, Solvay was nominated for the Association of Belgian Financial Analysts’ (ABAF) Prize for the Best Financial Information. The Award Commission’s report hails Solvay’s continuous improvement of its fi nancial and strategic information, the publication of quarterly results, its adoption of international accounting standards (International Financial Reporting Standards) and an increasingly appreciated Internet site. Shareholder and Investor Clubs In 2005, the Solvay group actively continued its meetings with individual investors. To give some examples: - In March 2005, Mr A. Michielsen met with over 250 readers of Cash magazine, including members of investor clubs from the Investa and VFBB federations. - In April, Solvay was present at the ‘Investors Happening’ organized in Antwerp by the Flemish Association of Investors and Investor Clubs. - In September a lunch presentation took place with the INVESTA private investors’ federation and - In November, for the second time, Solvay presented itself to French investors by taking part at the Actionaria Fair at the Paris Palais des Congrès. Roadshows and meetings for professionals Roadshows and meetings with Group management are organized regularly for international professionals (analysts, portfolio managers, press, etc.) In 2005 over 400 contacts were established at meetings and events organized in Europe (Brussels, London, Paris, Frankfurt, Geneva, Zurich, Milan, ...), the United States and Canada. The annual analysts’ meeting in October, which is also open to the fi nancial press, was attended by some 80 analysts and investors from 8 European countries and the USA. Attendees examined Group strategy, major changes in the activities portfolio and recent developments, and in particular the strategic directions of the Pharmaceuticals Sector for the coming years. Conference calls with management are systematically organized, currently on a quarterly basis, to comment on Group results. In March 2005 a special conference was also organized to present and comment on the acquisition of Fournier Pharma. The Group wishes to thank its shareholders, and all others, in particular fi nancial journalists and analysts, for the confi dence they continue to express in Solvay.
Contacts: The Investor Relations Team is ready to assist shareholders and investors with any question concerning the activities of the Solvay group and the Solvay share and to provide any information (annual report, detailed accounts of Solvay S.A., information by sector or market,…): Solvay S.A. Investor Relations Rue du Prince Albert 33 B -1050 Brussels (Belgium) Phone: +32 2 509 60 16 Fax: +32 2 509 72 40 also by e-mail: investor.relations@solvay.com. A specifi c Internet site, www.solvay-investors.com provides shareholders and investors with useful information and documentation together with fi nancial and strategic information about the Group. Visitors to the site can also register with the shareholders’ and investors’ club to be notifi ed by e-mail of the publication of most of this information. For further information on the ADRs, a hotline is also available at 1-800-428-4237 (from the United States and Canada) and at 1-781-575-4328 (from other countries). 109 Solvay Global Annual Report 2005
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48:
Meeting The Science Days organized
Page 49 and 50:
Human Resources The Group’s fi ve
Page 51 and 52:
“ At the end of this seminar, all
Page 53 and 54:
Sustainable Development 2005 saw th
Page 55 and 56:
Accident frequency rate Persons wor
Page 57 and 58:
Management Report New records for S
Page 59 and 60:
Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97 and 98: PORTUGAL Fournier Farmaceutica Port
Page 99 and 100: List of fully consolidated Group co
Page 101 and 102: Solvay Salz Holding GmbH, Hannover
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111: The Solvay share compared with the
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?